Bill Solander is a first-chair trial lawyer who hasn’t forgotten the importance of knowing his cases intimately. For pharmaceutical clients as well as those in other industries, he brings a hands-on style to high-stakes patent disputes, with particularly deep experience in ANDA litigation.
Mentored by the renowned patent litigator Robert Baechtold until his retirement, Bill has earned his own “fantastic reputation” as “a truly excellent patent litigator.”(Chambers USA). He has led cases involving subject matter as varied as prescription antiarrhythmic drugs, protein synthesis, new battery technologies, and prescription sleep aids, and he has secured victories in an equally wide variety of forums, including federal district and appellate courts, the Patent Trial and Appeal Board, and civil arbitrations.
Bill has also developed significant knowledge of IP laws and civil justice systems outside the United States, and frequently counsels clients who seek his strategic advice in connection with business and legal activities in foreign jurisdictions. He has been involved with trial teams on litigation in Australia, Canada, Germany, Israel and the UK, among other countries.
Bill speaks and writes frequently on litigation strategy, polymorph patents, and Hatch-Waxman litigation.
LEO Pharmaceutical Products, Ltd. v. Rea
Federal Circuit (2013)
At the Federal Circuit, Bill secured a reversal of a finding by the Board of Patent Appeals and Interferences that a patent covering LEO Pharma’s topical antipsoriatic medication Taclonex was obvious. Applying the “substantial evidence” standard of review, the appellate panel noted that LEO Pharma’s burden was “a challenging one,” but determined that Bill and his team had met it.